Case Report
BibTex RIS Cite

A fatal side effect of piperacillin/tazobactam use: a case report.

Year 2021, Volume: 3 Issue: 3, 119 - 121, 28.12.2021

Abstract

Drug-induced QT prolongation with T wave inversion is a complex regulatory and clinical problem due to the rarity of this potentially fatal adverse incident. A 68-year-old female patient was receiving piperacillin/tazobactam therapy for a complicated urinary tract infection. She has had normal ECG findings before the antibacterial therapy. After the treatment, the patient worsens due to long QT which is predisposed to torsades de pointes. As a result of the researches, it was understood that the cause of long QT was piperacillin/tazobactam. We aimed to present a rare case in which we detected drug-induced QTc prolongation with piperacillin/tazobactam in clinical practice.

Supporting Institution

The authors declare no conflict of interest or any financial support.

References

  • :1. Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is "normal". J Cardiovasc Electrophysiol. 2006;17(3):333-336. doi:10.1111/j.1540-8167.2006.00408.x
  • 2. Antzelevitch C, Shimizu W. Cellular mechanisms underlying the long QT syndrome. Curr Opin Cardiol. 2002;17(1):43-51. doi:10.1097/00001573-200201000-00007
  • 3. Woosley RL. QT Drug Lists by Risk Groups. AZ: Arizona Center for Research and Education on Therapeutics. Published 2009. Accessed September 1, 2021. http:// www.azcert.org/medical-pros/drug-lists/drug-lists.cfm
  • 4. Katchman AN, Koerner J, Tosaka T, Woosley RL, Ebert SN. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther. 2006;316(3):1098-1106. doi:10.1124/jpet.105.093393
  • 5. Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf. 2010;33(4):303-314. doi:10.2165/11531850-000000000-00000
  • 6. Panduranga P, Al-Mukhaini M, Rajarao MP. Multi-factorial causes of torsade de pointes in a hospitalised surgical patient. Sultan Qaboos Univ Med J. 2013;13(1):152-155. doi:10.12816/0003211
  • 7. Piperacillin and tazobactam: Drug information. Published December 6, 2020. Accessed semtember 1, 2021. . https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information search=piperacillin%20tazobactam&source=panel_search_result&selectedTitle=1~104&usage_type=panel&kp_tab=drug_general&display_rank=1#F210382
Year 2021, Volume: 3 Issue: 3, 119 - 121, 28.12.2021

Abstract

References

  • :1. Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is "normal". J Cardiovasc Electrophysiol. 2006;17(3):333-336. doi:10.1111/j.1540-8167.2006.00408.x
  • 2. Antzelevitch C, Shimizu W. Cellular mechanisms underlying the long QT syndrome. Curr Opin Cardiol. 2002;17(1):43-51. doi:10.1097/00001573-200201000-00007
  • 3. Woosley RL. QT Drug Lists by Risk Groups. AZ: Arizona Center for Research and Education on Therapeutics. Published 2009. Accessed September 1, 2021. http:// www.azcert.org/medical-pros/drug-lists/drug-lists.cfm
  • 4. Katchman AN, Koerner J, Tosaka T, Woosley RL, Ebert SN. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther. 2006;316(3):1098-1106. doi:10.1124/jpet.105.093393
  • 5. Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf. 2010;33(4):303-314. doi:10.2165/11531850-000000000-00000
  • 6. Panduranga P, Al-Mukhaini M, Rajarao MP. Multi-factorial causes of torsade de pointes in a hospitalised surgical patient. Sultan Qaboos Univ Med J. 2013;13(1):152-155. doi:10.12816/0003211
  • 7. Piperacillin and tazobactam: Drug information. Published December 6, 2020. Accessed semtember 1, 2021. . https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information search=piperacillin%20tazobactam&source=panel_search_result&selectedTitle=1~104&usage_type=panel&kp_tab=drug_general&display_rank=1#F210382
There are 7 citations in total.

Details

Primary Language English
Subjects Intensive Care
Journal Section Case Reports
Authors

Murat Duyan 0000-0002-6420-3259

Serhat Günlü 0000-0003-4346-0085

Ali Sarıdaş 0000-0002-2725-6001

Basar Cander 0000-0002-3308-5843

Yıldızhan Solaç 0000-0002-2040-4569

Publication Date December 28, 2021
Submission Date September 8, 2021
Acceptance Date November 8, 2021
Published in Issue Year 2021 Volume: 3 Issue: 3

Cite

APA Duyan, M., Günlü, S., Sarıdaş, A., Cander, B., et al. (2021). A fatal side effect of piperacillin/tazobactam use: a case report. Eurasian Journal of Critical Care, 3(3), 119-121.
AMA Duyan M, Günlü S, Sarıdaş A, Cander B, Solaç Y. A fatal side effect of piperacillin/tazobactam use: a case report. Eurasian j Crit Care. December 2021;3(3):119-121.
Chicago Duyan, Murat, Serhat Günlü, Ali Sarıdaş, Basar Cander, and Yıldızhan Solaç. “A Fatal Side Effect of piperacillin/tazobactam Use: A Case Report”. Eurasian Journal of Critical Care 3, no. 3 (December 2021): 119-21.
EndNote Duyan M, Günlü S, Sarıdaş A, Cander B, Solaç Y (December 1, 2021) A fatal side effect of piperacillin/tazobactam use: a case report. Eurasian Journal of Critical Care 3 3 119–121.
IEEE M. Duyan, S. Günlü, A. Sarıdaş, B. Cander, and Y. Solaç, “A fatal side effect of piperacillin/tazobactam use: a case report”., Eurasian j Crit Care, vol. 3, no. 3, pp. 119–121, 2021.
ISNAD Duyan, Murat et al. “A Fatal Side Effect of piperacillin/tazobactam Use: A Case Report”. Eurasian Journal of Critical Care 3/3 (December 2021), 119-121.
JAMA Duyan M, Günlü S, Sarıdaş A, Cander B, Solaç Y. A fatal side effect of piperacillin/tazobactam use: a case report. Eurasian j Crit Care. 2021;3:119–121.
MLA Duyan, Murat et al. “A Fatal Side Effect of piperacillin/tazobactam Use: A Case Report”. Eurasian Journal of Critical Care, vol. 3, no. 3, 2021, pp. 119-21.
Vancouver Duyan M, Günlü S, Sarıdaş A, Cander B, Solaç Y. A fatal side effect of piperacillin/tazobactam use: a case report. Eurasian j Crit Care. 2021;3(3):119-21.

Indexing and Abstracting

1493315074 2096820551208572097121274